ArQule, Inc.
(NASDAQ : ARQL)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
AMRNAmarin Corporation Plc Sponsored ADR
-0.17%17.232.0%$167.17m
PRGOPerrigo Co. Plc
2.30%45.906.8%$129.01m
SAGESAGE Therapeutics, Inc.
2.44%139.799.5%$123.27m
JAZZJazz Pharmaceuticals Plc
1.32%129.072.2%$95.40m
GWPHGW Pharmaceuticals PLC Sponsored ADR
2.07%137.296.3%$80.20m
PTLAPortola Pharmaceuticals, Inc.
3.59%26.537.7%$62.92m
ICPTIntercept Pharmaceuticals, Inc.
-0.19%113.4518.6%$56.49m
MNKMallinckrodt Plc
3.72%20.6421.1%$45.66m
CTLTCatalent Inc
1.12%35.612.4%$42.08m
AXSMAxsome Therapeutics, Inc.
-1.92%8.162.7%$41.76m
UTHRUnited Therapeutics Corporation
1.37%115.7514.4%$40.50m
ICLRICON Plc
-0.18%133.184.1%$40.47m
ENDPEndo International Plc
-1.52%9.708.9%$38.65m
HZNPHorizon Pharma plc
-1.71%21.847.4%$28.32m
MDCOMedicines Company
0.25%20.0021.8%$27.91m

Company Profile

ArQule, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of targeted therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes novel small molecule drugs in areas of unmet need that will dramatically extend and improve the lives of its patients. Its proprietary pipeline includes ARQ 531, Derazantinib, Miransertib, ARQ 751, ARQ 761. The company was founded in 1993 and is headquartered in Burlington, MA.